Regulus Therapeutics Inc (NASDAQ: RGLS) has experienced a rise in its stock price by 10.64 compared to its previous closing price of 1.41. However, the company has seen a gain of 4.70% in its stock price over the last five trading days. prnewswire.com reported 2024-11-07 that Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results and provided a corporate update for the third quarter ended September 30, 2024. “We have remained focused on rapidly progressing RGLS8429 for the potential treatment of ADPKD and were pleased to announce the completion of enrollment in our fourth and final cohort of the Phase 1b MAD study last month.
Is It Worth Investing in Regulus Therapeutics Inc (NASDAQ: RGLS) Right Now?
Moreover, the 36-month beta value for RGLS is 1.58. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RGLS is 52.92M and currently, short sellers hold a 3.19% of that float. On November 13, 2024, RGLS’s average trading volume was 359.70K shares.
RGLS’s Market Performance
RGLS stock saw an increase of 4.70% in the past week, with a monthly gain of 2.63% and a quarterly increase of 1.30%. The volatility ratio for the week is 8.46%, and the volatility levels for the last 30 days are 8.09% for Regulus Therapeutics Inc (RGLS). The simple moving average for the past 20 days is 3.90% for RGLS’s stock, with a -16.74% simple moving average for the past 200 days.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with Oppenheimer repeating the rating for RGLS by listing it as a “Outperform.” The predicted price for RGLS in the upcoming period, according to Oppenheimer is $7 based on the research report published on August 02, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $6. The rating they have provided for RGLS stocks is “Outperform” according to the report published on March 18th, 2024.
B. Riley FBR Inc. gave a rating of “Neutral” to RGLS, setting the target price at $1 in the report published on March 28th of the previous year.
RGLS Trading at 0.72% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.84% of loss for the given period.
Volatility was left at 8.09%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares surge +4.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.64% lower at present.
During the last 5 trading sessions, RGLS rose by +4.70%, which changed the moving average for the period of 200-days by +23.81% in comparison to the 20-day moving average, which settled at $1.5015. In addition, Regulus Therapeutics Inc saw 21.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGLS starting from Collier Kathryn J, who purchase 4,000 shares at the price of $1.82 back on Jul 25 ’24. After this action, Collier Kathryn J now owns 6,740 shares of Regulus Therapeutics Inc, valued at $7,280 using the latest closing price.
CALSADA CRISPINA, the Chief Financial Officer of Regulus Therapeutics Inc, sale 5,468 shares at $1.19 during a trade that took place back on Jan 18 ’24, which means that CALSADA CRISPINA is holding 5,782 shares at $6,510 based on the most recent closing price.
Stock Fundamentals for RGLS
Current profitability levels for the company are sitting at:
- -147.67 for the present operating margin
- 0.19 for the gross margin
The net margin for Regulus Therapeutics Inc stands at -137.84. The total capital return value is set at -0.51. Equity return is now at value -72.36, with -63.31 for asset returns.
Based on Regulus Therapeutics Inc (RGLS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -75.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -518.56.
Currently, EBITDA for the company is -30.88 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 252.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.65.
Conclusion
To wrap up, the performance of Regulus Therapeutics Inc (RGLS) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
